셀트리온 제약

O lymphoma

· Relapsed or chemotherapy-resistant follicular lymphoma (B-cell non-Hodgkin lymphoma IWF classification type B, C, D)

· Combined with chemotherapy in previously untreated follicular lymphoma

· Maintenance therapy after induction therapy in follicular lymphoma

· CD20-positive diffuse large B-cell non-Hodgkin lymphoma (DLCL) [Should be administered in combination with CHOP chemotherapy (8 cycles consisting of cyclophosphamide, doxorubicin, vincristine, and prednisolone)]

O Chronic lymphocytic leukemia

· Combined with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukemia

O Rheumatoid arthritis

· Combination therapy with methotrexate in moderately to severely active rheumatoid arthritis that has not responded adequately to one or more TNF antagonist regimens

· When used in combination with methotrexate, it reduces the progression of joint damage (as measured by X-ray) and improves physical function.

O Wegener's granulomatosis and microscopic polyangiitis

· Concomitant administration with glucocorticoids in Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) in adults

50mL/vial, 10mL/vial (1mL 중 rituximab 10mg)

623800061 ( 196769원-2020.02.01) ,( 817823원-2020.02.01)